Home > Oncology > ASCO 2021 > Melanoma > Novel dual checkpoint blockade improves progression-free survival in melanoma

Novel dual checkpoint blockade improves progression-free survival in melanoma

Presented By
Dr Evan Lipson, Johns Hopkins University, MD, USA
Conference
ASCO 2021
Trial
Phase 3, RELATIVITY-047
First results of the phase 3 RELATIVITY-047 trial validated the efficacy of dual checkpoint blockade demonstrated with the LAG-3 inhibitor relatlimab and nivolumab in patients with advanced melanoma. Lymphocyte-activation gene 3 (LAG-3) regulates an immune checkpoint pathway that inhibits T-cell activity and is upregulated in many tumour types including melanoma [1]. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores effector function of exhausted T cells [2]. Relatlimab in combination with nivolumab modulates potentially synergistic immune checkpoint pathways and can enhance anti-tumour immune responses [3]. RELATIVITY-047 (NCT03470922) is a global, randomised, double-blind, phase 2/3 study evaluating the combination of relatlimab plus nivolumab treatment in first-line advanced melanoma. In this trial, 714 pat...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on